Stock CMPS COMPASS PATHWAYS PLC
Add to a list
To use this feature you must be a member
Log inSign up

All News COMPASS Pathways plc

Equities

CMPS

US20451W1018

Market Closed - Nasdaq
Other stock markets
 03:59:48 2024-06-04 pm EDT 		5-day change 1st Jan Change
7.661 USD +0.80% Intraday chart for COMPASS Pathways plc +2.97% -12.45%
01:00pm FDA panel to review psychedelic drug MDMA for first time RE
May. 22 Clarify Pharma confirms name change to File Forge AN

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
FDA panel to review psychedelic drug MDMA for first time
RE
Clarify Pharma confirms name change to File Forge
AN
COMPASS Pathways : 2024 AGM Voting Results
PU
Transcript : COMPASS Pathways plc - Shareholder/Analyst Call
Transcript : COMPASS Pathways plc, Q1 2024 Earnings Call, May 08, 2024
COMPASS Pathways plc Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
GL
Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder
CI
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
GL
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
GL
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
GL
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement to Inform the Training of Healthcare Providers and Delivery Model for Comp360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
CI
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing
MT
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing
MT
Clarify Pharma to change name to File Forge Technology
AN
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing
MT
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing
MT
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing
MT
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing
MT
Morgan Stanley Initiates COMPASS Pathways at Overweight With $30 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMPS Stock
  4. News COMPASS Pathways plc